Quick Takeaways
- ARWR - ARROWHEAD PHARMACEUTICALS, INC. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$37,654,163.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 17 Insiders of ARROWHEAD PHARMACEUTICALS, INC.
- Symbol
- ARWR on Nasdaq
- Location
- Pasadena, CA
What Changed
- Buy value: ; sell value: $37,654,162.
- Net share flow: -603,931.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$37,654,163.
Buys
$0
Shares: 0
Insiders: 0
Sells
$37,654,163
Shares: 603,931
Insiders: 9
Net
-$37,654,163
Shares: -603,931
Insiders: -9
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 33,095 | $0 | $2,326,185 | -$2,326,185 |
| 3-6 | 0 | 510,836 | $0 | $33,602,978 | -$33,602,978 |
| 6-9 | 0 | 60,000 | $0 | $1,725,000 | -$1,725,000 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
ARROWHEAD PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer, Director | $251,799,942 | -$24,010,564 | -8.7% | Filing P/S | 02 Jan 2026 |
| Patrick O'Brien | Coo | $36,342,471 | -$3,123,349 | -7.9% | Mixed | 06 Jan 2026 |
| James C. Hamilton | Chief Medical Officer | $17,021,850 | -$5,651,561 | -25% | Filing P/S | 23 Apr 2026 |
| Daniel Joseph Apel | Chief Financial Officer | $11,716,127 | -$934,285 | -7.4% | Filing P/S | 22 Apr 2026 |
| Kenneth Allen Myszkowski | Chief Financial Officer | $8,967,476 | Filing P/S | 04 Jan 2025 | ||
| Javier San Martin | Chief Medical Officer | $7,417,833 | Mixed | 04 Jan 2024 | ||
| Michael S. Perry | Director | $4,977,736 | -$991,738 | -17% | Mixed | 16 Dec 2025 |
| Mauro Ferrari | Director | $4,833,710 | -$1,020,513 | -17% | Filing P/S | 26 Dec 2025 |
| James Hassard | Chief Commercial Officer | $3,951,878 | Mixed | 22 Jun 2021 | ||
| William D. Waddill | Director | $3,876,262 | -$566,038 | -13% | Filing P/S | 19 Dec 2025 |
| Tracie Oliver | Chief Commercial Officer | $3,213,265 | Filing P/S | 02 Jul 2024 | ||
| Douglas B. Given | Director | $2,736,641 | Filing P/S | 16 Dec 2024 | ||
| Victoria Vakiener | Director | $2,443,095 | -$679,491 | -22% | Filing P/S | 19 Dec 2025 |
| Adeoye Y. Olukotun | Director | $2,300,928 | -$676,623 | -23% | Filing P/S | 19 Dec 2025 |
| Hongbo Lu | Director | $2,224,021 | Mixed | 16 Dec 2025 | ||
| Douglas S. Ingram | Director | $1,869,396 | Mixed | 16 Dec 2025 | ||
| Marianne de Backer | Director | $1,168,448 | Mixed | 10 Jan 2023 |
Top shareholders of ARROWHEAD PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
12%
from 13D/G
|
21,318,582
|
$1,415,340,659 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
11%
|
15,293,121
|
$1,015,310,304 | — | 31 Dec 2025 | |
| Avoro Capital Advisors LLC |
13F
13D/G
|
Company |
8.3%
from 13D/G
|
10,625,000
|
$705,393,750 | — | 31 Dec 2025 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
|
Vanguard Portfolio Management |
5.2%
|
7,269,957
|
$455,826,304 | $0 | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
|
Vanguard Capital Management |
5%
|
7,081,293
|
$443,997,071 | $0 | 31 Mar 2026 | |
| FMR LLC |
13F
|
Company |
4.7%
|
6,520,408
|
$432,889,919 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
13D/G
|
Company · STATE STREET CORPORATION |
4.6%
from 13D/G
|
6,403,830
|
$425,150,274 | — | 31 Dec 2025 | |
| Christopher Richard Anzalone |
3/4/5
|
Chief Executive Officer, Director |
2.7%
|
3,792,739
|
$251,799,942 | -$24,010,564 | 02 Jan 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
3,264,963
|
$216,798,525 | — | 31 Dec 2025 | |
| Slate Path Capital LP |
13F
|
Company |
1.8%
|
2,523,500
|
$167,535,165 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.6%
|
2,175,645
|
$144,441,072 | — | 31 Dec 2025 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
1.5%
|
2,087,953
|
$138,619,200 | — | 31 Dec 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,832,997
|
$121,692,671 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.3%
|
1,832,946
|
$121,689,285 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.3%
|
1,769,340
|
$117,466,483 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
1.2%
|
1,704,464
|
$113,159,365 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,677,522
|
$111,370,685 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.1%
|
1,500,476
|
$99,616,602 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.1%
|
1,476,005
|
$97,992,146 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.97%
|
1,353,719
|
$89,873,404 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.96%
|
1,346,257
|
$89,378,003 | — | 31 Dec 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.94%
|
1,311,727
|
$87,085,554 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
0.91%
|
1,280,446
|
$84,997,093 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.9%
|
1,260,380
|
$83,676,628 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.73%
|
1,028,736
|
$68,635,932 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.7%
|
987,287
|
$65,545,984 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.64%
|
900,000
|
$59,751,000 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.63%
|
887,848
|
$58,944,211 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.6%
|
838,818
|
$55,690,000 | — | 31 Dec 2025 | |
| Western Financial Corp/CA |
13F
|
Company |
0.58%
|
820,239
|
$54,455,667 | — | 31 Dec 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.51%
|
715,539
|
$47,504,634 | — | 31 Dec 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.49%
|
684,889
|
$45,469,781 | — | 31 Dec 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.47%
|
663,262
|
$44,033,964 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.44%
|
622,029
|
$41,296,505 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.44%
|
611,910
|
$40,624,705 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.42%
|
584,716
|
$38,819,295 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.39%
|
550,000
|
$36,514,500 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.39%
|
547,758
|
$36,365,654 | — | 31 Dec 2025 | |
| Patrick O'Brien |
3/4/5
|
COO |
0.39%
|
547,408
|
$36,342,471 | -$3,123,349 | 06 Jan 2026 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.34%
|
478,514
|
$31,768,544 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.34%
|
474,259
|
$31,486,055 | — | 31 Dec 2025 | |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC |
13F
|
Company |
0.34%
|
470,000
|
$31,203,300 | — | 31 Dec 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.3%
|
422,731
|
$28,065,111 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.29%
|
400,184
|
$26,568,216 | — | 31 Dec 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.28%
|
398,204
|
$26,436,764 | — | 31 Dec 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.28%
|
395,311
|
$26,244,697 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.27%
|
376,216
|
$24,976,980 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.27%
|
375,371
|
$24,920,881 | — | 31 Dec 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.26%
|
370,000
|
$24,564,300 | — | 31 Dec 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.25%
|
352,395
|
$23,395,468 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for ARROWHEAD PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James C. Hamilton | ARWR | Common Stock | Sale | -4.22% | $750,000 | $75.00 | -10,000 | 226,958 | 23 Apr 2026 | Direct |
| Daniel Joseph Apel | ARWR | Common Stock | Sale | -7.44% | $934,285 | $71.35 | -13,095 | 162,905 | 22 Apr 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -4.05% | $641,900 | $64.19 | -10,000 | 236,958 | 05 Mar 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Award | 43.6% | 75,000 | 246,958 | 06 Jan 2026 | Direct | ||
| Daniel Joseph Apel | ARWR | Common Stock | Award | 74.1% | 75,000 | 176,200 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Award | 15.9% | 75,000 | 547,408 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Gift | -0.53% | -2,500 | 472,408 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Sale | -9.44% | $3,123,349 | $63.11 | -49,493 | 474,908 | 05 Jan 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -18.9% | $2,534,661 | $63.11 | -40,164 | 171,958 | 05 Jan 2026 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.35% | $871,703 | $66.10 | -13,187 | 3,792,739 | 02 Jan 2026 | Direct |
| Patrick O'Brien | ARWR | Common Stock | Gift | -0.53% | -2,800 | 524,401 | 31 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -1.34% | $3,575,575 | $69.13 | -51,726 | 3,805,926 | 29 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Options Exercise | 1.36% | 51,726 | 3,857,652 | 29 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Stock Option (right to buy Common Stock) | Options Exercise | -100% | -51,726 | 0 | 29 Dec 2025 | Direct | ||
| Mauro Ferrari | ARWR | Common Stock | Sale | -9.83% | $527,100 | $70.00 | -7,530 | 69,053 | 26 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.33% | $861,340 | $68.44 | -12,586 | 3,805,926 | 22 Dec 2025 | Direct |
| William D. Waddill | ARWR | Common Stock | Sale | -12.9% | $566,038 | $67.65 | -8,367 | 56,563 | 19 Dec 2025 | Direct |
| Victoria Vakiener | ARWR | Common Stock | Sale | -21.9% | $679,491 | $67.68 | -10,040 | 35,723 | 19 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.35% | $909,683 | $67.66 | -13,445 | 3,818,512 | 19 Dec 2025 | Direct |
| Adeoye Y. Olukotun | ARWR | Common Stock | Sale | -22.9% | $676,623 | $67.66 | -10,000 | 33,600 | 19 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -2.17% | $5,443,462 | $64.04 | -85,000 | 3,831,957 | 17 Dec 2025 | Direct |
| Mauro Ferrari | ARWR | Common Stock | Award | 11.4% | 7,819 | 76,583 | 16 Dec 2025 | Direct | ||
| Hongbo Lu | ARWR | Common Stock | Award | 16.6% | 7,819 | 54,982 | 16 Dec 2025 | Direct | ||
| Michael S. Perry | ARWR | Common Stock | Award | 6.78% | 7,819 | 123,059 | 16 Dec 2025 | Direct | ||
| Victoria Vakiener | ARWR | Common Stock | Award | 20.6% | 7,819 | 45,763 | 16 Dec 2025 | Direct | ||
| Douglas S. Ingram | ARWR | Common Stock | Award | 20.4% | 7,819 | 46,215 | 16 Dec 2025 | Direct | ||
| Adeoye Y. Olukotun | ARWR | Common Stock | Award | 21.8% | 7,819 | 43,600 | 16 Dec 2025 | Direct | ||
| William D. Waddill | ARWR | Common Stock | Award | 13.7% | 7,819 | 64,930 | 16 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -1.37% | $3,398,187 | $62.58 | -54,298 | 3,916,957 | 16 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -3.17% | $8,950,615 | $68.85 | -130,000 | 3,971,255 | 15 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Award | 4.59% | 180,000 | 4,101,255 | 12 Dec 2025 | Direct | ||
| Michael S. Perry | ARWR | Common Stock | Sale | -12.4% | $991,738 | $61.03 | -16,250 | 115,240 | 05 Dec 2025 | Direct |
| Mauro Ferrari | ARWR | Common Stock | Sale | -11.3% | $493,412 | $56.39 | -8,750 | 68,764 | 28 Nov 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -8.62% | $700,000 | $35.00 | -20,000 | 212,122 | 01 Oct 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -6.07% | $450,000 | $30.00 | -15,000 | 232,122 | 12 Sep 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -5.72% | $375,000 | $25.00 | -15,000 | 247,122 | 02 Sep 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -3.46% | $187,780 | $20.00 | -9,389 | 262,122 | 15 Aug 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -0.22% | $12,220 | $20.00 | -611 | 271,511 | 13 Aug 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.